NICE had already begun the appraisal process on DCvax-L back in 2018, which was eagerly getting ahead of itself when compared to its actions on other medical treatments. They still needed the top line data (or more detailed data) to move forward, which obviously Northwest was unable to provide at that time, so the efforts have been suspended. NICE will once again move it forward (probably rather quickly) as soon as that information is provided to them.
News 
Market Data 
Discover 
